 "Lupin gains as US arm gets NDA approval for antibiotic Suprax")
Pharma major Lupin is trading higher on the bourses today after its US arm Lupin Pharmaceuticals received the US Food and Drugs Administration (FDA) approval to market and sell antibiotic Suprax (Cefixime) capsules in 400mg strength.
Cefixime is used to treat infections like tonsilitis and acute bronchitis among others. The approval will expand Lupin’s range of Suprax dosage. It is currently available as 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.
[caption id=“attachment_332672” align=“alignleft” width=“380” caption=“Lupin shares are up 1 percent at Rs 538.20 on NSE in morning trade.”]
[/caption]
Lupin shares are up 1 percent at Rs 538.20 on NSE in morning trade.
Commenting on the approval, Nilesh Gupta, Group President & Executive Director, Lupin Limited said “We are happy to receive this approval. The new dosage form will add to our growing SUPRAX franchise and gives health care providers and patients a new formulation to treat the indicated infections. The approval of SUPRAX capsules is one more example of our ongoing commitment to serving our customers and addressing their needs.”
According to Prashant Nair, Director & Deputy Head of Research, Citi India, Lupin is likely to outperform not just the market but its peers in the pharma sector as well.